Pharma market reports growth in September
4 years, 2 months ago

Pharma market reports growth in September

Deccan Chronicle  

Chennai: Notwithstanding the higher base, the pharma market grew 4.5 per cent in the month of September. Cardiac drugs grew by 17 per cent, vitamins, minerals and nutrients by 16.3 per cent and anti-diabetic therapy posted growth of 6.5 per cent last month. Meanwhile, Crisil expects pharma exports to grow by 11-12 per cent this fiscal, better than last year’s 10 per cent growth. On the other hand, steady demand for chronic therapies pertaining to lifestyle diseases should help keep domestic formulation sales growth at 5-6 per cent,” said Tanvi Shah, associate director, CRISIL Ratings.

Growth Pharma Cent Volumes  prices  growth  domestic  market  volumes  reports  pharma  sales  medicines  grew  therapies  cent

History of this topic

Pharma Exports in Two Months Rise 8.8% to $4.73 Billion: Pharmexcil Director General Udaya Bhaskar
5 months, 3 weeks ago

Pharma Exports in Two Months Rise 8.8% to $4.73 Billion: Pharmexcil Director General Udaya Bhaskar

Deccan Chronicle  

15 blockbuster drugs worth $ 112 billion to go off patent by 2029. Will provide a tremendous growth opportunity for Indian pharmaceutical companies by another $ 10 billion. This would provide a tremendous growth opportunity for Indian pharmaceutical companies by another $ 10 billion, said Pharmaceutical Export Promotion Council of India director general R Udaya Bhaskar. Off-patent drugs apart, PLI …

Indian pharma industry to hit $57 billion by FY25
1 year, 5 months ago

Indian pharma industry to hit $57 billion by FY25

Live Mint  

New Delhi: Domestic pharmaceutical industry will likely hit $57 billion by FY25, along with expansion in operating margins by 100-150 basis points, according to a report by CareEdge Ratings. During FY18 to FY23, the Indian pharmaceutical industry has logged a a compound annual growth rate of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in …

Domestic pharmaceutical market to reach $130 billion by 2030: Economic Survey
1 year, 10 months ago

Domestic pharmaceutical market to reach $130 billion by 2030: Economic Survey

The Hindu  

India's domestic pharmaceutical market is estimated to reach $130 billion by 2030 and the pharma industry has sustained its growth momentum after the pandemic, according to the Economic Survey 2022-23. On the home front, the Survey said, "India's domestic pharmaceutical market is estimated at $41 billion in 2021 and is likely to grow to 65 billion by 2024 and is …

Pharma exports rise by 4.22% to $14.57 billion during April-October in current fiscal
2 years ago

Pharma exports rise by 4.22% to $14.57 billion during April-October in current fiscal

The Hindu  

Pharmaceutical exports from India registered a growth of 4.22% to reach $14.57 billion during the April-October period despite a negative trend last month, according to a senior official of an export promotion body under Government of India. Udaya Bhaskar, Director General of Pharmaceuticals Export Promotion Council of India which is an organisation under the Ministry of Commerce, said he was …

India takes another step towards becoming pharmacy of the world as exports grow by 103% since 2013-14
2 years, 7 months ago

India takes another step towards becoming pharmacy of the world as exports grow by 103% since 2013-14

Firstpost  

India’s top five pharma export destinations are the US, UK, South Africa, Russia and Nigeria. India’s pharma exports in 2021-22 sustained a positive growth despite the global trade disruptions and drop in demand for COVID-related medicines, it added. “Indian pharma companies enabled by their price competitiveness and good quality, have made a global mark, with 60 per cent of the …

Q4 Results Preview: Margins of Pharma companies likely to remain under pressure in the March quarter
2 years, 8 months ago

Q4 Results Preview: Margins of Pharma companies likely to remain under pressure in the March quarter

Live Mint  

The Indian pharmaceuticals sector has been under pressure from the ongoing Russia-Ukraine war as a majority of pharma companies have a strong presence in both countries. The report estimates EBITDA in 4QFY22E to be sequentially lower for the majority of Indian generic pharma companies on account of lower gross margins due to an increase in raw material costs and sustained …

Discover Related